Page last updated: 2024-12-10
coelichelin
Description
coelichelin: a tetrapeptide siderophore from Streptomyces coelicolor produced by nonribosomal peptide biosynthesis; has been sequenced [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
coelichelin : A tetrapeptide hydroxamate siderophore that is isolated from Streptomyces coelicolor. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (6)
| Synonym |
|---|
| (2s)-2-[[(2r)-2-amino-5-[formyl(hydroxy)amino]pentanoyl]amino]-5-[[(2r,3r)-2-[[(2r)-2-amino-5-[formyl(hydroxy)amino]pentanoyl]amino]-3-hydroxybutanoyl]-hydroxyamino]pentanoic acid |
| 2-[2-amino-5-(formyl-hydroxy-amino)-pentanoylamino]-5-({2-[2-amino-5-(formyl-hydroxy-amino)-pentanoylamino]-3-hydroxy-butyryl}-hydroxy-amino)-pentanoic acid |
| coelichelin |
| CHEBI:80049 |
| n(2)-(n(5)-formyl-n(5)-hydroxy-d-ornithyl)-n(5)-(n(5)-formyl-n(5)-hydroxy-d-ornithyl-d-allothreonyl)-n(5)-hydroxy-l-ornithine |
| Q27149200 |
Research Excerpts
Bioavailability
Roles (2)
| Role | Description |
|---|
| siderophore | Any of low-molecular-mass iron(III)-chelating compounds produced by microorganisms for the purpose of the transport and sequestration of iron. |
| bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
| Class | Description |
|---|
| tetrapeptide | Any molecule that contains four amino-acid residues connected by peptide linkages. |
| hydroxamic acid | A compound, RkE(=O)lNHOH, derived from an oxoacid RkE(=O)l(OH) (l =/= 0) by replacing -OH with -NHOH, and derivatives thereof. Specific examples of hydroxamic acids are preferably named as N-hydroxy amides. |
| formamides | Amides with the general formula R(1)R(2)NCHO (R(1) and R(2) can be H). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 25.98
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 25.98 (24.57) | | Research Supply Index | 2.48 (2.92) | | Research Growth Index | 5.14 (4.65) | | Search Engine Demand Index | 26.67 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |